|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
45,560,000 |
Market
Cap: |
12.06(M) |
Last
Volume: |
1,167,076 |
Avg
Vol: |
555,803 |
52
Week Range: |
$0.2646 - $0.2646 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Protalix BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system. Co.'s proprietary ProCellEx platform is being used to manufacture its marketed product, Elelyso®, for the treatment of Gaucher disease. Co. is also developing, via ProCellEx, a pipeline of products. Co.'s clinical development program for pegunigalsidase alfa, or PRX-102, for the potential treatment of Fabry disease. In addition, Co. is developing uricase, or PRX-115, for the treatment of refractory gout.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
64,516 |
64,516 |
242,516 |
Total Buy Value |
$0 |
$90,484 |
$90,484 |
$348,299 |
Total People Bought |
0 |
1 |
1 |
2 |
Total Buy Transactions |
0 |
1 |
1 |
3 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bashan Dror |
PRESIDENT AND CEO |
|
2023-10-19 |
4 |
B |
$1.40 |
$90,484 |
D/D |
64,516 |
132,516 |
0.01 |
- |
|
Bashan Dror |
President and CEO |
|
2023-08-15 |
4 |
A |
$0.00 |
$0 |
I/I |
800,000 |
1,885,458 |
|
- |
|
Naos Yaron |
Sr. VP, Operations |
|
2023-08-15 |
4 |
A |
$0.00 |
$0 |
I/I |
187,344 |
200,817 |
|
- |
|
Rubin Eyal |
Sr. VP and CFO |
|
2023-08-15 |
4 |
A |
$0.00 |
$0 |
I/I |
201,903 |
570,000 |
|
- |
|
Hayon Yael |
VP, Research & Development |
|
2023-08-15 |
4 |
A |
$0.00 |
$0 |
I/I |
35,115 |
35,115 |
|
- |
|
Schwartz Aharon |
Director |
|
2023-01-03 |
4 |
B |
$1.42 |
$155,815 |
D/D |
110,000 |
174,000 |
2.39 |
- |
|
Bashan Dror |
President and CEO |
|
2022-04-11 |
4 |
B |
$1.50 |
$102,000 |
D/D |
68,000 |
68,000 |
2.81 |
- |
|
Rubin Eyal |
Sr. VP and CFO |
|
2022-02-25 |
4 |
A |
$0.00 |
$0 |
I/I |
121,951 |
368,097 |
|
- |
|
Bashan Dror |
President and CEO |
|
2022-02-25 |
4 |
A |
$0.00 |
$0 |
I/I |
637,531 |
1,085,458 |
|
- |
|
Oren Dan |
10% Owner |
|
2021-06-03 |
4 |
S |
$2.25 |
$1,932,304 |
D/D |
(857,506) |
3,637,314 |
|
- |
|
Oren Dan |
10% Owner |
|
2021-06-02 |
4 |
S |
$2.56 |
$156,553 |
D/D |
(61,211) |
4,494,820 |
|
- |
|
Oren Dan |
10% Owner |
|
2021-02-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,556,031 |
|
- |
|
Bashan Dror |
President and CEO |
|
2020-08-11 |
4 |
A |
$0.00 |
$0 |
I/I |
447,927 |
447,927 |
|
- |
|
Rubin Eyal |
Sr. VP and CFO |
|
2020-08-11 |
4 |
A |
$0.00 |
$0 |
I/I |
246,146 |
246,146 |
|
- |
|
Schwartz Aharon |
Director |
|
2020-04-07 |
4 |
B |
$2.43 |
$155,264 |
D/D |
64,000 |
64,000 |
2.39 |
- |
|
Boudes Pol F |
Director |
|
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
40 |
|
- |
|
Manor Moshe |
President & CEO |
|
2017-05-16 |
4 |
B |
$0.81 |
$40,500 |
D/D |
50,000 |
50,000 |
2.81 |
- |
|
Camber Capital Management Llc |
10% Owner |
|
2016-12-02 |
4 |
S |
$0.32 |
$792,000 |
I/I |
(2,500,000) |
10,775,000 |
|
- |
|
Shaaltiel Yoseph |
Executive VP, R&D |
|
2016-09-15 |
4 |
OE |
$0.00 |
$122 |
D/D |
122,162 |
585,916 |
|
- |
|
Yossi Maimon |
Vice President & CFO |
|
2015-12-14 |
4 |
B |
$0.78 |
$7,800 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
Camber Capital Management Llc |
10% Owner |
|
2015-10-19 |
4 |
B |
$1.00 |
$4,000,436 |
I/I |
4,000,423 |
13,275,000 |
1.5 |
- |
|
Camber Capital Management Llc |
10% Owner |
|
2015-10-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9,274,577 |
|
- |
|
Bronfeld Zeev |
Director |
|
2014-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
324,372 |
2,162,481 |
|
- |
|
Bronfeld Zeev |
Director |
|
2014-10-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,509,948) |
0 |
|
- |
|
Bio-Cell Ltd |
10% Owner |
|
2014-09-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(8,556,371) |
1,509,948 |
|
- |
|
29 Records found
|
|
Page 1 of 2 |
|
|